PART I Overview We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the tumor microenvironment, or TME, and limits systemic toxicity. This approach was deployed in the...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001628280-26-022010 | EDGAR | 92K words |
| 2025-03-27 | 2024-12-31 | 0002023658-25-000012 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0002023658-25-000109 | EDGAR | 63K words |
| 2025-08-12 | 2025-06-30 | 0002023658-25-000098 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0002023658-25-000039 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0002023658-24-000002 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001628280-26-021868 | EDGAR | 3K words |
| 2026-02-26 | 0001193125-26-076560 | EDGAR | — |
| 2026-02-19 | 0001628280-26-009808 | EDGAR | — |
| 2026-01-12 | 0001628280-26-001766 | EDGAR | — |
| 2025-12-08 | 0002023658-25-000112 | EDGAR | — |
| 2025-11-10 | 0002023658-25-000107 | EDGAR | — |
| 2025-08-12 | 0002023658-25-000094 | EDGAR | — |
| 2025-06-12 | 0002023658-25-000082 | EDGAR | — |
| 2025-06-06 | 0002023658-25-000063 | EDGAR | — |
| 2025-05-13 | 0002023658-25-000034 | EDGAR | — |
29 total filings indexed. 13 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0002023658 |
| Ticker | BCAX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.bicara.com |
| Listed | 2024-09-13 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report